Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Genome sequencing data reveals new insights into Epstein-Barr virus immunity

The Epstein-Barr virus (EBV) can cause certain types of cancer or autoimmune diseases, but how the body controls this common viral infection is largely unknown.

19 Feb 2026

Fred Hutch scientists reach crucial milestone in blocking Epstein Barr virus

Fred Hutch Cancer Center scientists reached a crucial milestone in blocking Epstein Barr virus (EBV), a pathogen estimated to infect 95% of the global population that is linked to multiple types of cancer, neurodegenerative diseases and other chronic health conditions.

17 Feb 2026

Optimization of CAR T cells to destroy solid tumors

A team led by LMU physician Sebastian Kobold has found a way to allow the body's immune system to destroy solid tumors.

16 Feb 2026

ASH releases new guidelines for treating leukemia in adolescents and young adults

The American Society of Hematology (ASH) released guidelines on frontline management of acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs), as well as the management of relapsed or refractory disease in this population.

12 Feb 2026

Case report examines potential cancer risks after mRNA vaccination

A new case report was published in Volume 17 of Oncotarget on February 6, 2026, titled "Exploring the potential link between mRNA COVID-19 vaccinations and cancer: A case report with a review of haematopoietic malignancies with insights into pathogenic mechanisms."

12 Feb 2026

FDA label update expands CAR T access for primary CNS lymphoma

Dana-Farber Cancer Institute-led research helped drive an FDA label update for axicabtagene ciloleucel (Yescarta) that removes a prior exclusion for patients with primary central nervous system lymphoma, a rare and aggressive lymphoma of the brain and spinal cord.

9 Feb 2026

Epigenetic plasticity in germinal center B cells may help explain lymphoma origins

Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During their preparation for this battle, B cells transiently revert to a more flexible, or plastic, stem-cell-like state in the lymph nodes, according to a new preclinical study from Weill Cornell Medicine investigators.

30 Dec 2025

Precision immunotherapy for TRBC2-positive T-cell malignancies

Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets TRBC2-positive T-cell cancers, expanding a precision approach they established in 2024 for TRBC1-positive tumors.

22 Dec 2025

Revolutionary quantum sensors could enable earlier cancer diagnosis and treatment

A revolutionary quantum sensing project that could transform cancer treatment by tracking how immune cells interact with tumors has been awarded a prestigious £2 million Future Leaders Fellowship.

16 Dec 2025

Chemotherapy may reduce HIV-infected T cells

Advancements in HIV/AIDS research, drug development and clinical practice since the 1980s have made it possible for people living with HIV to lead long, productive lives and keep the virus in check at undetectable levels and nontransmissible as long as therapy is maintained.

15 Dec 2025

Early relapse predicts poor survival in mature nodal T-cell lymphoma

Mature nodal T-cell lymphoma is a type of rare and aggressive blood cancer. Limited data make it difficult to identify high-risk patients or tailor treatment strategies, so most patients receive similar care despite differences in disease characteristics and outcomes.

12 Dec 2025

Disrupted genome architecture drives lymphoma development

Cancer isn't just about broken genes-it's about broken architecture. Imagine a city where roads suddenly vanish, cutting off neighborhoods from essential services.

10 Dec 2025

Pirtobrutinib shows superior outcomes compared to common first-line combination treatment for CLL/SLL

In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile when compared with bendamustine plus rituximab (BR) in patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

10 Dec 2025

Sterilized fermented beverage targets obesity and type 2 diabetes pathways in computational study

Researchers profiled a terminally sterilized probiotic-fermented MFH beverage and identified aporphine alkaloids and flavonoids with favorable predicted ADMET properties. Integrated network pharmacology, molecular docking, and 100-ns MD simulations suggest multi-target engagement of metabolic-inflammatory pathways relevant to obesity and type 2 diabetes.

9 Dec 2025

People exposed to Agent Orange face higher risk of developing myelodysplastic syndrome

A new national study shows for the first time that people exposed to Agent Orange face a higher risk of developing myelodysplastic syndrome (MDS), tend to develop it earlier, and often have more aggressive disease that is more likely to progress to acute myeloid leukemia.

9 Dec 2025

New antibody shows ability to overcome treatment resistance in blood cancers and solid tumors

In a new preclinical study, researchers from The University of Texas MD Anderson Cancer Center developed an antibody therapy called 77A that showed an ability to overcome treatment resistance in blood cancers, such as myeloma and lymphoma, as well as solid tumors.

9 Dec 2025

Patients receiving T-cell redirecting therapies can safely be monitored at home

Patients who receive T-cell redirecting therapies are typically hospitalized for several days after treatment to watch for side effects.

9 Dec 2025

Powerful prognostic marker could enable early identification of high-risk cancer patients

Aggressive T-cell lymphoma is a rare and devastating form of blood cancer with a very low five-year survival rate.

8 Dec 2025

Combination therapy may boost survival for people with aggressive lymphoma

A new clinical trial suggests that pairing bispecific antibodies and antibody-drug conjugates with CAR T-cell therapy may sharply boost one-year progression-free survival for people with aggressive lymphoma.

8 Dec 2025

Lymphocyte levels help predict outcomes after CAR T-cell therapy in non-Hodgkin lymphoma

Measuring the lymphocytes - white blood cells that fight infection - in a patient's blood can be used to predict outcomes in non-Hodgkin lymphoma patients who receive CAR T-cell therapy, according to research from physicians at Fox Chase Cancer Center and Temple Health.

8 Dec 2025

Lymphoma News and Research

Further Reading

Genome sequencing data reveals new insights into Epstein-Barr virus immunity

Fred Hutch scientists reach crucial milestone in blocking Epstein Barr virus

Optimization of CAR T cells to destroy solid tumors

ASH releases new guidelines for treating leukemia in adolescents and young adults

Case report examines potential cancer risks after mRNA vaccination

FDA label update expands CAR T access for primary CNS lymphoma

Epigenetic plasticity in germinal center B cells may help explain lymphoma origins

Precision immunotherapy for TRBC2-positive T-cell malignancies

Revolutionary quantum sensors could enable earlier cancer diagnosis and treatment

Chemotherapy may reduce HIV-infected T cells

Early relapse predicts poor survival in mature nodal T-cell lymphoma

Disrupted genome architecture drives lymphoma development

Pirtobrutinib shows superior outcomes compared to common first-line combination treatment for CLL/SLL

Sterilized fermented beverage targets obesity and type 2 diabetes pathways in computational study

People exposed to Agent Orange face higher risk of developing myelodysplastic syndrome

New antibody shows ability to overcome treatment resistance in blood cancers and solid tumors

Patients receiving T-cell redirecting therapies can safely be monitored at home

Powerful prognostic marker could enable early identification of high-risk cancer patients

Combination therapy may boost survival for people with aggressive lymphoma

Lymphocyte levels help predict outcomes after CAR T-cell therapy in non-Hodgkin lymphoma

Everything you should know about lymphoma eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News